Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
219.1 USD | -1.51% | -4.58% | -5.31% |
May. 28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
May. 14 | Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.88 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.35 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.31% | 39.92B | B | ||
+43.36% | 54.64B | B- | ||
+37.52% | 38.82B | A | ||
+14.75% | 26.86B | B- | ||
-12.56% | 26.22B | C | ||
-22.45% | 18.78B | B | ||
+25.12% | 12.21B | B+ | ||
+0.04% | 12.16B | B+ | ||
+26.04% | 11.94B | C+ | ||
-11.83% | 10.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.